The diagnosis and treatment of non-tuberculous mycobacterium disease in children

doi:10.3969/j.issn.1000-6621.2021.09.021

Abstract

ZHENG Hui-wen, SHEN A-dong. The diagnosis and treatment of non-tuberculous mycobacterium disease in children[J]. Chinese Journal of Antituberculosis, 2021, 43(9): 979-982. doi: 10.3969/j.issn.1000-6621.2021.09.021

References 26

[1]	Saxena S, Spaink HP, Forn-Cuní G. Drug Resistance in Nontuberculous Mycobacteria: Mechanisms and Models. Biology (Basel), 2021, 10(2):96. doi: 10.3390/biology10020096. doi: 10.3390/biology10020096
[2]	Tebruegge M, Pantazidou A, MacGregor D, et al. Nontuberculous Mycobacterial Disease in Children-Epidemiology, Diagnosis & Management at a Tertiary Center. PLoS One, 2016, 11(1):e0147513. doi: 10.1371/journal.pone.0147513. doi: 10.1371/journal.pone.0147513 URL
[3]	Haverkamp MH, Arend SM, Lindeboom JA, et al. Nontuberculous mycobacterial infection in children: a 2-year prospective surveillance study in the Netherlands. Clin Infect Dis, 2004, 39(4):450-456. doi: 10.1086/422319. doi: 10.1086/422319 pmid: 15356803
[4]	Pham-Huy A, Robinson JL, Tapiéro B, et al. Current trends in nontuberculous mycobacteria infections in Canadian children: A pediatric investigators collaborative network on infections in Canada (PICNIC) study. Paediatr Child Health, 2010, 15(5):276-282. doi: 10.1093/pch/15.5.276. doi: 10.1093/pch/15.5.276 URL
[5]	Reuss AM, Wiese-Posselt M, Weissmann B, et al. Incidence rate of nontuberculous mycobacterial disease in immunocompetent children: a prospective nationwide surveillance study in Germany. Pediatr Infect Dis J, 2009, 28(7):642-644. doi: 10.1097/INF.0b013e3181978e8e. doi: 10.1097/INF.0b013e3181978e8e URL
[6]	Asiimwe BB, Bagyenzi GB, Ssengooba W, et al. Species and genotypic diversity of non-tuberculous mycobacteria isolated from children investigated for pulmonary tuberculosis in rural Uganda. BMC Infect Dis, 2013, 13:88. doi: 10.1186/1471-2334-13-88. doi: 10.1186/1471-2334-13-88 pmid: 23413873
[7]	王宇. 全国第五次结核病流行病学抽样调查资料汇编. 北京: 军事医学科学出版社, 2011: 15-18.
[8]	Zimmermann P, Curtis N, Tebruegge M. Nontuberculous mycobacterial disease in childhood-update on diagnostic approaches and treatment. J Infect, 2017, 74 Suppl 1: S136-S142. doi: 10.1016/S0163-4453(17)30204-9. doi: 10.1016/S0163-4453(17)30204-9
[9]	Loizos A, Soteriades ES, Pieridou D, et al. Lymphadenitis by non-tuberculous mycobacteria in children. Pediatr Int, 2018, 60(12):1062-1067. doi: 10.1111/ped.13708. doi: 10.1111/ped.13708
[10]	López-Varela E, García-Basteiro AL, Santiago B, et al. Non-tuberculous mycobacteria in children: muddying the waters of tuberculosis diagnosis. Lancet Respir Med, 2015, 3(3):244-256. doi: 10.1016/S2213-2600(15)00062-4. doi: 10.1016/S2213-2600(15)00062-4 URL
[11]	Danielides V, Patrikakos G, Moerman M, et al. Diagnosis, management and surgical treatment of non-tuberculous mycobacterial head and neck infection in children. ORL J Otorhinolaryngol Relat Spec, 2002, 64(4):284-289. doi: 10.1159/000064138. doi: 10.1159/000064138 URL
[12]	Willemse SH, Oomens MAEM, De Lange J, et al. Diagnosing nontuberculous mycobacterial cervicofacial lymphadenitis in children: A systematic review. Int J Pediatr Otorhinolaryngol, 2018, 112:48-54. doi: 10.1016/j.ijporl.2018.06.034. doi: 10.1016/j.ijporl.2018.06.034 URL
[13]	Chung J, Ince D, Ford BA, et al. Cutaneous Infections Due to Nontuberculosis Mycobacterium: Recognition and Management. Am J Clin Dermatol, 2018, 19(6):867-878. doi: 10.1007/s40257-018-0382-5. doi: 10.1007/s40257-018-0382-5 pmid: 30168084
[14]	Santa Cruz DJ, Strayer DS. The histologic spectrum of the cutaneous mycobacterioses. Hum Pathol, 1982, 13(5):485-495. doi: 10.1016/s0046-8177(82)80032-4. doi: 10.1016/s0046-8177(82)80032-4 pmid: 6804365
[15]	Lu M, Saddi V, Britton PN, et al. Disease caused by non-tuberculous mycobacteria in children with cystic fibrosis. Paediatr Respir Rev, 2019, 29:42-52. doi: 10.1016/j.prrv.2018.05.001. doi: 10.1016/j.prrv.2018.05.001
[16]	Martiniano SL, Davidson RM, Nick JA. Nontuberculous mycobacteria in cystic fibrosis: Updates and the path forward. Pediatr Pulmonol, 2017, 52(S48):S29-S36. doi: 10.1002/ppul.23825. doi: 10.1002/ppul.23825 URL
[17]	Morgan MB, Reves RR, Wilson ML, et al. Comparison of BACTEC 12B vs solid media for the recovery of Mycobacterium avium complex from blood cultures in AIDS patients. Diagn Microbiol Infect Dis, 1997, 28(1):45-48. doi: 10.1016/s0732-8893(97)89159-6. doi: 10.1016/s0732-8893(97)89159-6 URL
[18]	Schoenfeld N, Haas W, Richter E, et al. Recommendations of the German Central Committee against Tuberculosis (DZK) and the German Respiratory Society (DGP) for the Diagnosis and Treatment of Non-tuberculous Mycobacterioses. Pneumo-logie, 2016, 70(4):250-276. doi: 10.1055/s-0041-111494. doi: 10.1055/s-0041-111494
[19]	Zimmermann P, Tebruegge M, Curtis N, et al. The management of non-tuberculous cervicofacial lymphadenitis in children: A systematic review and meta-analysis. J Infect, 2015, 71(1):9-18. doi: 10.1016/j.jinf.2015.02.010. doi: 10.1016/j.jinf.2015.02.010 pmid: 25727993
[20]	Torretta S, Gaffuri M, Ibba T, et al. Surgical treatment of non-tuberculous mycobacterial lymphadenitis in children: Our experience and a narrative review. Int J Immunopathol Pharmacol, 2018, 32:2058738418806413. doi: 10.1177/2058738418806413. doi: 10.1177/2058738418806413
[21]	Meoli A, Deolmi M, Iannarella R, et al. Non-Tuberculous Mycobacterial Diseases in Children. Pathogens, 2020, 9(7):553. doi: 10.3390/pathogens9070553. doi: 10.3390/pathogens9070553 URL
[22]	Andrew EC, Connell T, Robinson P, et al. Pulmonary Mycobacterium abscessus complex in children with cystic fibrosis: A practical management guideline. J Paediatr Child Health, 2019, 55(5):502-511. doi: 10.1111/jpc.14427. doi: 10.1111/jpc.14427 URL
[23]	Lindeboom JA. Conservative wait-and-see therapy versus antibiotic treatment for nontuberculous mycobacterial cervicofacial lymphadenitis in children. Clin Infect Dis, 2011, 52(2):180-184. doi: 10.1093/cid/ciq070. doi: 10.1093/cid/ciq070 pmid: 21288841
[24]	Shafran SD, Singer J, Zarowny DP, et al. A Comparison of Two Regimens for the Treatment of Mycobacterium avium Complex Bacteremia in AIDS: Rifabutin, Ethambutol, and Clarithromycin versus Rifampin, Ethambutol, Clofazimine, and Ciprofloxacin. N Engl J Med, 1996, 335:377-383. doi: 10.1056/NEJM199608083350602. doi: 10.1056/NEJM199608083350602 URL
[25]	Karakousis PC, Moore RD, Chaisson RE. Mycobacterium avium complex in patients with HIV infection in the era of highly activeantiretroviral therapy. Lancet Infect Dis, 2004, 4:557-565. doi: 10.1016/S1473-3099(04)01130-2. doi: 10.1016/S1473-3099(04)01130-2 pmid: 15336223
[26]	Griffith DE, Aksamit T, Brown-Elliott BA, et al. An official ATS/IDSA statement: diagnosis, treatment, and prevention of nontuberculous mycobacterial diseases. Am J Respir Crit Care Med, 2007, 175(4):367-416. doi: 10.1164/rccm.200604-571ST. doi: 10.1164/rccm.200604-571ST URL

The diagnosis and treatment of non-tuberculous mycobacterium disease in children

RichHTML

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References 26

Related Articles 15

Recommended Articles

Metrics

Comments

[1]	Li Yuhong, Mei Jinzhou, Su Wei, Ruan Yunzhou, Liu Yushu, Zhao Yanlin, Liu Xiaoqiu. Analysis of the treatment outcomes and influencing factors of rifampicin-resistant pulmonary tuberculosis patients aged 65 and above in China from 2015 to 2021 [J]. Chinese Journal of Antituberculosis, 2025, 47(4): 408-415.
[2]	Wu Xuan, Zhang Yanqiu, Xu Jiying, Meng Dan, Sun Dingyong. Analysis of factors influencing the treatment outcomes of patients with pulmonary tuberculosis and diabetes mellitus in Henan Province (2019—2023) [J]. Chinese Journal of Antituberculosis, 2025, 47(4): 425-431.
[3]	An Yuan, Bai Yunlong, Zhao Qinglong, Ma Jianjun, Jiang Xue, Pan Yan, Gao Ying, Gao Zhihui. Analysis of treatment outcomes and influencing factors of patients with pulmonary tuberculosis complicated with diabetes mellitus in Jilin Province,2018—2022 [J]. Chinese Journal of Antituberculosis, 2025, 47(4): 432-438.
[4]	Yang Haixia, Zhang Xiaoyan, Huang Yi, Li Qiu. Effective and safety of concurrent intensity-modulated radiotherapy and anti-tuberculosis chemotherapy in patients with active pulmonary tuberculosis comorbid with thoracic tumor [J]. Chinese Journal of Antituberculosis, 2025, 47(3): 312-321.
[5]	Xue Yu, Yang Xinting, Wang Guirong, Liu Fangchao, Lei Xuan, Zhang Jing, Li Liang. Analysis of risk factors for death in emergency pulmonary tuberculosis patients and risk model construction [J]. Chinese Journal of Antituberculosis, 2025, 47(2): 189-194.
[6]	Wang Dafu, Ma Xiaoxue, Wang Yun, Li Fudong, Rao Wen, Gong Tingting, Li Shijun, Li Jinlan. Analysis of risk factors for patient delay and adverse treatment outcomes among patients with pulmonary tuberculosis and diabetes mellitus in Guizhou Province, 2016—2023 [J]. Chinese Journal of Antituberculosis, 2025, 47(2): 201-209.
[7]	Liang Linlong, Pei Yi, Zhou Haiyi, Xie Qifang, Zhang Feng, Jiang Jie, Liu Fuqiang. The epidemiological characteristics and trends of tuberculosis among children aged 0-14 years in Hunan Province from 2014 to 2023 [J]. Chinese Journal of Antituberculosis, 2025, 47(1): 29-35.
[8]	Li Fudong, Ma Xiaoxue, Zhou Jian, Wang Dafu, Zhang Yueying, Gong Tingting, Rao Wen, Hong Feng, Li Shijun, Li Jinlan. Characteristics and treatment outcome analysis of MTB/HIV dual infection patients in Guizhou Province from 2018 to 2023 [J]. Chinese Journal of Antituberculosis, 2025, 47(1): 36-43.
[9]	Shi Yilin, Gu Yan. Meta-analysis of the efficacy, adverse reactions, and fatality rate of glucocorticoid combined with anti-tuberculosis drugs in the treatment of tuberculous serositis [J]. Chinese Journal of Antituberculosis, 2025, 47(1): 77-86.
[10]	Fan Jun, Wang Heng, Lan Tinglong, Dong Weijie, Tang Kai, Li Yuan, Yan Guangxuan, Xu Shangsheng, Kang Zhigang, Qin Shibing. Clinical characteristics and surgical outcomes of 12 cases of non-tuberculous mycobacterial spondylitis [J]. Chinese Journal of Antituberculosis, 2025, 47(1): 87-95.
[11]	Ye Zhiteng, Ren Fei, Wang Hua, Yang Ming, Chen Yu, Chen Xiaohong, Wang Yun, Fan Lin. Treatment outcomes and influencing factors in elderly patients with multidrug/rifampicin-resistant pulmonary tuberculosis: a national multicenter, retrospective cohort study [J]. Chinese Journal of Antituberculosis, 2024, 46(9): 1023-1029.
[12]	Huang Tao, Jian Huiyong, Wang Xinqi, Liu Nianqiang, Yipar Aihaiti, Wang Mingzhe, Jiayinati Jingesi, Wang Senlu. Analysis of influencing factors of treatment outcomes in patients with pulmonary tuberculosis complicated with diabetes mellitus in Xinjiang Uygur Autonomous Region [J]. Chinese Journal of Antituberculosis, 2024, 46(9): 1083-1088.
[13]	Li Qinjing, Jiao Weiwei, Wang Zeming, Shen Adong. Interpretation of clinical standards for drug-susceptible tuberculosis in children and adolescents [J]. Chinese Journal of Antituberculosis, 2024, 46(8): 877-885.
[14]	Zhao Xueyao, Han Lijun, Feng Guodong, Qin Guixiang, Sun Li. Clinical analysis of low dose thalidomide in the adjuvant treatment of 20 cases of adult tuberculous meningitis complicated with paradoxical reactions [J]. Chinese Journal of Antituberculosis, 2024, 46(8): 910-917.
[15]	Liu Siyuan, Cun Xinhua, Wu Lei, Bai Ping, Zhou Yi, Rao Tao, Chen Lin, Dou Jichen, Zhao Heng, Wang Yizhou. Application of individualized 3D printed artificial vertebral body replacement in reconstruction of complex tuberculosis-affected spine [J]. Chinese Journal of Antituberculosis, 2024, 46(8): 918-925.